ERBB2 and breast carcinoma: Trastuzumab (TRZ), a monoclonal antibody targeted to the extracellular domain of the human epidermal growth factor receptor 2 (HER2) protein, is used in the treatment of HER2-positive breast cancer [3,10,11].